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Abstract
Dynamic treatment regimes (DTRs) aim to formalize personalized medicine by
tailoring treatment decisions to individual patient characteristics. G-estimation for
DTR identification targets the parameters of a structural nested mean model known
as the blip function from which the optimal DTR is derived. Despite considerable
work deriving such estimation methods, there has been little focus on extending G-
estimation to the case of non-additive effects, non-continuous outcomes or on model
selection. We demonstrate how G-estimation can be more widely applied through the
use of iteratively-reweighted least squares procedures, and illustrate this for log-linear
models. We then derive a quasi-likelihood function for G-estimation within the DTR
framework, and show how it can be used to form an information criterion for blip model
selection. These developments are demonstrated through application to a variety of
simulation studies as well as data from the Sequenced Treatment Alternatives to Relieve
Depression study.
Keywords: Adaptive treatment strategies; Dynamic treatment regimes; Iteratively-
reweighted least squares; Quasi-likelihood Information Criterion; Structural nested
models.
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1. INTRODUCTION
Dynamic treatment regimes (DTRs) - sequences of decision rules that take patient informa-
tion as input and output recommended treatments - are part of a rapidly expanding literature
on personalized medicine (Chakraborty and Moodie 2013). By tailoring treatments to indi-
vidual patient characteristics, DTRs are able to improve long-term outcomes for a population
when compared with more traditional non-tailored approaches. Identification of the opti-
mal regime (which maximizes expected outcome) is a major challenge due to, for example,
delayed treatment effects and covariate-dependent treatment assignment.
Numerous methods have been proposed for optimal DTR estimation. A general class
of DTR estimation approaches relies on structural nested mean models (SNMMs, Robins
1994; Vansteelandt and Goetghebeur 2003). In our formulation, the SNMM parameterizes
the difference between the conditional expectation of the outcome following observed treat-
ment with that of a counterfactual outcome under a (potentially unobserved) treatment
regime. By estimating the parameters of this model we are then able to identify the op-
timal DTR, i.e. the sequence of treatment decisions that maximizes the expected outcome
across all patients. This general approach of parameterizing and estimating components of
the outcome mean model is used in a variety of specific DTR estimation methods, includ-
ing Q-learning (Watkins 1989; Sutton and Andrew 1998), dynamic weighted least squares
(Wallace and Moodie 2015), and G-estimation (Robins 2004), the last of which is the focus
of this paper.
Almost all of the methodological developments for DTR estimation have focused on con-
tinuous outcomes and additive effects of treatment on the expected counterfactual outcome,
with time-to-event outcomes included as a special case. Estimation for discrete outcomes,
or for effects of treatment on non-additive scales has received little attention. A recent ex-
ception is the work of Moodie et al. (2014) who used generalized additive models to apply
Q-learning in this setting. Thall et al. (2000), meanwhile, considered a likelihood-based ap-
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proach in the case of a binary outcome. Such examples are rare, however, and typically
grounded in methods that do not offer a great deal of flexibility or robustness in modeling.
The presentation (and implementation) of G-estimation primarily for continuous outcomes
therefore represents an important limitation of the approach.
Even for continuous outcomes, there has been little focus on model selection in the
context of G-estimation. The methods listed above all implicitly assume that the SNMMs
upon which they rely are correctly (or possibly over-) specified. Very little work has been
published related to the problem of choosing between a set of candidate models or model
checking. Exceptions include the diagnostic plots of Rich et al. (2010) and the method
of Wallace et al. (2016) that exploits the so-called double-robustness property (discussed
below) for model assessment. Neither of these, however, assess the component of the model
quantifying the effect of treatment – i.e., the blip model – alone, and can at best assess the
validity of both the blip model and another component model simultaneously.
In this paper, we present two generalizations of G-estimation. First, we derive and
illustrate how iteratively-reweighted least squares (IRLS) may be used to implement G-
estimation in a discrete-outcome scenario using log-linear models. We then present a new
approach to model selection when using G-estimation for DTRs based on a Quasi-likelihood
Information Criterion (QIC). Our QIC formulation is applicable to G-estimation procedures
in general, but we demonstrate how the QIC can be applied to G-estimation in the DTR
setting, encompassing multiple stages of treatment for both the cases of continuous and
count outcomes.
2. DTRS AND G-ESTIMATION
We establish notation by considering G-estimation in its conventional form, where effects
of exposure are additive and a linear model is presumed for the counterfactual outcomes.
We consider a cohort of subjects on whom data are gathered at fixed intervals (such as
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visits to a physician) or at fixed clinical decision points (diagnosis, remission, and so on),
with a treatment decision made at each of these time points. Our objective is to identify
the sequence of treatment decision rules (the DTR) which maximizes a subject’s long-term
expected outcome (defined such that larger values are preferred). We assume there are a
total of J successive treatment decisions (or stages): y denotes observed patient outcome;
aj denotes the stage j treatment decision (j = 1, ..., J), with a
0
j denoting “no treatment”
(such as a control or standard care); hj denotes the covariate matrix containing patient
information (history) prior to the jth treatment decision. The history can include previous
treatments a1, ..., aj−1 along with non-treatment information xj. In addition, over- and
underline notation is used to indicate the past and future, respectively. For example aj
denotes the vector of treatment decisions up to and including the stage j decision, while
aj+1 denotes the last J − j decisions (from stage j + 1 up to and including stage J). The
optimal treatment at any given stage is denoted aoptj .
The (stage j) optimal blip-to-reference (or simply blip) function is defined as
γj(hj, aj) = E[Y (aj−1, aj,a
opt
j+1)− Y (aj−1, a0j ,aoptj+1)|hj]
which is the expected difference in outcome when using a reference treatment a0j instead of
aj at stage j, in subjects with history hj who receive optimal treatment across the remaining
J− j intervals (aoptj+1). The optimal treatment at stage j maximizes the blip. Under additive
local rank preservation (see 2.1.3 of Chakraborty and Moodie 2013), we can decompose the
expectation of the observed potential outcome as
E[Y (aJ)] = E[Y
opt]−
J∑
j=1
[
γj(hj, a
opt
j )− γj(hj, aj)
]
where Y opt can be thought of as the optimal outcome that would be observed if the optimal
treatment was followed at every stage. The observed outcome y is then equal in expectation
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to the optimal outcome minus the difference in outcome between optimal and observed
treatment at each stage.
In practice, we assume γj(.) takes a known parametric form γj(hj, aj;ψj) with parameters
ψj. We then estimate ψj, and identify the optimal treatment regime by choosing, for each
subject, the treatment that maximizes the estimated blip. G-estimation is one method
which may be used to estimate ψj, and relies on two standard assumptions: the stable
unit treatment value assumption and the assumption of no unmeasured confounding (or
sequential randomization). The former means that a subject’s outcome is not influenced
by other subjects’ treatment allocation (Rubin 1980) and that the counterfactual outcome
under a particular treatment is equal to the observed outcome under that treatment; the
latter states that the treatment received at stage j is independent of any future (potential)
covariate or outcome, conditional on history hj.
Writing ψ
j
= (ψj,ψj+1, ...,ψJ), we define for each j, Gj(ψj) = y˜j−γj(hψj, aj ;ψj) where
y˜j = y +
∑J
k=j+1
[
γk(hψk, a
opt
k ;ψk)− γk(hψk, ak;ψk)
]
can be viewed as a pseudo-outcome
which we compute at each stage based on those ψ̂k (k > j), and hence â
opt
k already estimated.
Therefore
Gj(ψj) = y − γj(hj, aj;ψj) +
J∑
k=j+1
[
γk(hk, a
opt
k ;ψk)− γk(hk, ak;ψk)
]
and we can regard Gj(ψj) as being equal to the expected outcome with the effects of stage j
treatment ‘removed’ and the difference between optimal and observed treatment thereafter
‘added’. Under the above assumptions we have that E[Gj(ψj)|hj] = E[Y (aj−1, a0j ,a
opt
j+1)|hj]
which represents the expected outcome for a subject who receives treatment history aj−1 up
to stage j− 1, no treatment at stage j, and optimal treatment thereafter. We refer to Gj as
the stage j treatment-free outcome.
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To estimate the blip parameters ψj, G-estimation considers the set of functions
Uj(ψj ;βj;αj) = {Sj(Aj)− E[Sj(Aj)|hj;αj]} {Gj(ψj)− E[Gj(ψj)|hj;βj]}
where typically Sj(Aj) = ajhj. A fully efficient form of Sj(Aj) has been proposed (Robins
2004), but requires knowledge of the variance of Gj(ψj), which is rarely available in practice.
The estimating functions require the specification of a number of models, namely the stage
j blip model: γj(hψj , aj;ψj); the stage j treatment-free model: E[Gj(ψj)|hβj;βj]; and
the stage j treatment model: E[Aj |hαj;αj] (or, more generally, E[Sj(Aj)|hj;αj]), where
hψj , hβj and hαj are subsets of patient history that feature in the blip, treatment-free,
and treatment models, respectively. An important property of G-estimation is its double-
robustness: if the blip is correctly specified, then as long as at least one of the treatment
and treatment-free models is also correctly specified the resulting blip parameter estimators
will be consistent.
Because the functions Gj(ψj) depend on the observed outcome y and each blip model
from stage j onwards, G-estimation proceeds recursively, starting at the final stage J and
working backwards to stage 1. At each stage the above models are specified, and then the
following three steps are carried out:
1. Estimate the treatment model parameters α̂j by regressing the stage j treatment aj
on the treatment model covariates hαj .
2. Estimate the treatment-free model parameters βj by ‘regressing’ Gj(ψj) on hβj, where
rather than conducting a standard least squares regression, we instead solve the cor-
responding least squares equation to give β̂j(ψj, ψ̂j+1) in terms of the stage j blip
parameters ψj and the estimated blip parameters (ψ̂j+1) from previous stages.
3. Using the estimates α̂j and β̂j(ψj, ψ̂j+1) from steps 1 and 2, solve the equation
En[Uj(ψj; β̂j, α̂j)] = 0 to estimate ψj, where En denotes the mean over all subjects.
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We can then use the resulting blip parameter estimates ψ̂j to estimate the optimal stage j
treatment aoptj for each subject, and hence the function Gj−1(ψj−1), and repeat the above
steps until estimates are obtained for every stage of the analysis.
3. G-ESTIMATION FOR GENERALIZED LINEAR MODELS
The framework in section 2 is standard for G-estimation applications. It assumes a continu-
ous outcome, and that the treatment modifies the expected outcomes additively, that is, the
blip acts additively on the original outcome scale. The construction can be modified to be
applicable to discrete outcomes, but relaxing an assumption of additivity of the treatment
effect needs more care. In this section, we demonstrate how G-estimation may be general-
ized to handle other effect types, and show how estimation can be achieved using standard
computational approaches. Specifically, we will apply G-estimation for generalized linear
models by using iteratively-reweighted least squares.
3.1 G-estimation for multiplicative effects
For an arbitrary counterfactual outcome Y (a), the effect of exposure may be framed in
terms of the average potential outcome E[Y (a)], and contrasts comparing this average for
different exposures. For example, for a binary exposure we might consider the ratio of
expectations E[Y (1)]/E[Y (0)] rather than the expected ratio E[Y (1)/Y (0)]; this focuses on
population- rather than individual-level contrasts and avoids identifiability issues associated
with attempting to specify a joint model for {Y (0), Y (1)}.
For G-estimation, consider for illustration the two interval case; our approach will focus
on constructing models for E[Y (a1, a2)] using the decomposition
E[Y (a1, a2)] = E[Y (a
opt
1 , a
opt
2 )]
E[Y (a1, a
opt
2 )|h1]
E[Y (aopt1 , a
opt
2 )|h1]
E[Y (a1, a2)|h2]
E[Y (a1, a
opt
2 )|h2]
that is, using a multiplicative modification of the optimal outcome, and making a multiplica-
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tive rank preserving assumption. In this context, the blip function γj(hψj, aj) may be defined
as the ratio of expected counterfactual outcomes E[Y (aj−1, aj,a
opt
j+1)|hψj]/E[Y (aj−1, a0j ,aoptj+1)|hψj]
and the expected counterfactual outcome may be computed as
E[Y (aJ)|hJ ] = E[Y opt]
J∏
j=1
[
γj(hψj, aj)/γj(hψj, a
opt
j )
]
or equivalently
log(E[Y (aJ)|hJ ]) = log(E[Y opt])−
J∑
j=1
[
log
(
γj(hψj , a
opt
j )/γj(hψj, aj)
)]
,
giving rise to a stage-j pseudo-outcome analogous to that in the continuous outcome, linear
model setting as
y˜j = y ×
J∏
k=j+1
[(
γk(hψk, a
opt
k ;ψk)/γk(hψk, ak;ψk)
)]
, (1)
and hence Gj(ψj) = y˜j/γj(hψj, aj ;ψj). We then propose log-linear models for the treatment-
free and blip models
log
{
E[Gj(ψj)|hβj;βj]
}
= hβjβj log γj(hψj , aj;ψj) = ajhψjψj,
from which, via some rearrangement, the G-estimating functions become
Uj(ψj;βj;αj) = {Sj(Aj)−E[Sj(Aj)|hj;αj]} {Gj(ψj)− E[Gj(ψj)|hβj;βj]}
= {aj −E[Aj |hαj;αj]} {y˜j/ exp(ajhψjψj)− exp(hβjβj)}hψj.
Again suppressing stage-specific notation, and introducing subscript-i notation for subject
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i, G-estimation at each stage thus solves
0 =
n∑
i=1
dihψi(y˜i − µi(β,ψ)), (2)
with di = ai − E[Ai|hαi;α] and µi(β,ψ) = exp(hβiβ + aihψiψ). In section 3.2, we present
an IRLS algorithm to estimate blip parameters at each stage in the usual recursive manner.
Note that when the observed y value is zero, the pseudo-outcomes in (1) will also be zero
unless a further adjustment is made. A simple approach to this issue is to assume that when
y = 0, it is drawn from a Poisson distribution with mean 0.001 (or some other small value),
and replace y with its expectation. For example, for stage J − 1, after parameters ψJ are
estimated, the usual adjustment y˜J−1 = y ×
(
γJ(hψJ , â
opt
J ; ψ̂J)/γJ(hψJ , aJ ; ψ̂J)
)
becomes
y˜J−1 = 0.001×
(
γJ(hψJ , â
opt
J ; ψ̂J)/γJ(hψJ , aJ ; ψ̂J)
)
if y is zero; y˜J−1 is guaranteed non-negative.
3.2 Iteratively-reweighted least squares
We now demonstrate how G-estimation may proceed for log-linear models using IRLS. With-
out loss of generality we consider a single-stage example allowing us to suppress stage-specific
notation. The G-estimation equations, as written in (2) are of a standard form from which
IRLS may be used to estimate ψ. Suppose y has a mean function µ modeled using link
function g(·) and linear predictor vector η = hββ+ ahψψ such that µ = g−1(η). Denote the
variance function V (µ). We can then estimate ψ via IRLS using the following algorithm:
1. Set initial parameters β̂(0), ψ̂(0) and compute for each subject the initial linear predictor
η̂(0) = hββ̂
(0) + ahψψ̂
(0) and mean value µ̂(0) = g−1(η̂(0)).
2. Set ẑ
(1)
i = η̂
(0)
i + (yi − µ̂(0)i )g˙(µ̂(0)i ), ŵ(1)i = wi/[{g˙(µ̂(0)i )}2V (µ̂(0)i )]. Denote by D(1) the
diagonal matrix with (i, i) element d̂
(1)
i , and by A the diagonal matrix with (i, i) element ai,
the observed treatment for subject i.
3. Apply the G-estimation procedure to re-estimate β and ψ:
ψ̂(1) =
[
h⊤ψ (In − hβD)D(1)Ahψ
]−1 [
h⊤ψ (In − hβD)D(1)ẑ(1)
]
,
β̂(1) = (h⊤βD
(1)hβ)
−1h⊤βD
(1)(ẑ(1) −Ahψψ̂(1))
where hβD = hβ(h
⊤
βD
(1)hβ)
−1h⊤βD
(1), and In is the n× n identity matrix.
4. Define vectors η̂(1) = hββ̂
(1) +Ahψψ̂
(1) and µ̂(1) = g−1
(
η̂(1)
)
.
5. Return to 2 and iterate through 2-5 using µ̂(1) and η̂(1) as the updated starting values,
obtaining (µ̂(2),η̂(2)), then repeat to generate (µ̂(3),η̂(3)), and so on.
6. Repeat until µ̂(t) and η̂(t) satisfy
∣∣µ̂(t) − µ̂(t−1)∣∣ < ǫµ and/or ∣∣η̂(t) − η̂(t−1)∣∣ < ǫη for
tolerances ǫµ and ǫη.
The sequence of estimates produced by this algorithm converges to the solution of the G-
estimating equations.
4. G-ESTIMATION AND QUASI-LIKELIHOOD
Inference for SNMMs using G-estimation, unlike inference for more conventional models such
as generalized linear models (GLMs), is not likelihood-based and so established model selec-
tion approaches such as Akaike’s Information Criterion (AIC, Akaike 1973) cannot be directly
used within the DTR framework. However, we shall reframe the preceding presentations of
G-estimation to illustrate how quasi-likelihood theory may be applied.
4.1 Linear case
We assume the treatment-free model is linear in hβj, i.e. that E[Gj(ψj)|hβj;βj] = hβjβj.
Then by ordinary least squares, we may estimate βj as
β̂j(ψj, ψ̂j+1) =
[
h⊤βjhβj
]−1
h⊤βj(y˜j −Ajhψjψj).
10
For convenience we again suppress the subscript-j notation – all of what follows may be
applied on a stage-by-stage basis - and write ĥβ = hβj
[
h⊤βjhβj
]−1
h⊤βj. Substituting the
estimate of β̂ in terms of ψ, we may rewrite the estimating function vector as
U(ψ) = (Dhψ)
⊤(y˜ − hββ̂(ψ)−Ahψψ) = (Dhψ)⊤(y˜ − ĥβ(y˜ −Ahψψ)−Ahψψ)
= (Dhψ)
⊤
[
(In − ĥβ)(y˜ −Ahψψ)
]
= h⊤ψW (y˜ −Ahψψ)
where W = D⊤(In − ĥβ). From here, the estimation of ψ follows by
ψ̂ =
(
h⊤ψWAhψ
)−1
h⊤ψWy˜. (3)
The form of this estimator is straightforward (and is almost identical to a standard weighted
ordinary least squares estimator). This affords greater simplicity in implementation, as well
as giving a clear indication that quasi-likelihood methods may be easily applied.
We follow Wedderburn (1974) in defining the quasi-likelihood of ψ by writing µ = Ahψψ
and solving
∂Q
∂ψ
=
∂Q
∂µ
∂µ
∂ψ
= h⊤ψW (y˜ − µ),
yielding
Q(ψ) = ψ⊤h⊤ψWy˜ −
1
2
ψ⊤h⊤ψDAhψψ = ψ
⊤m− 1
2
ψ⊤Mψ (4)
where m = h⊤ψWy˜, M = h
⊤
ψWAhψ = h
⊤
ψD(In − ĥβ)Ahψ, and we ignore the constant
term. Because In − ĥβ is positive definite, M is positive semi-definite in expectation, and
thus provided n is large, this quasi-likelihood is uniquely maximized at ψ̂ in large samples.
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Furthermore, given the stage-by-stage, recursive nature of the G-estimation approach within
the DTR setting, we may derive this quasi-likelihood at each stage of an analysis.
4.2 Log-linear case
In the log-linear case we first reformulate (2), dividing through by exp(hββ) to give
0 =
n∑
i=1
dihψi(y
∗
i − µ∗i (ψ)) (5)
where y∗i = yi exp(−hβiβ) and µ∗i (ψ) = exp(aihψiψ). This moves the nuisance parameters
β into a pseudo-outcome y∗, framing the estimating equations more explicitly in terms of
the target blip parameters ψ, as in the linear case. This allows us to return to the theory of
Wedderburn and proceed as before by solving
∂Q
∂ψ
=
∂Q
∂µ∗
∂µ∗
∂ψ
= h⊤ψD(y˜
∗ − µ∗), (6)
but this does not yield a quasi-likelihood in a simple way. However, by appealing to the
IRLS procedure, and a recursive calculation, we compute a quasi-likelihood suitable for
model comparison by considering the sequence of linear approximations to the log-linear
estimating equations implied by (4). The IRLS procedure produces a solution to (6) by
utilizing a quadratic approximation to the actual quasi-likelihood at the maximizing value;
by standard theory the solution is an o(1) approximation to the actual maximizing value
of the quasi-likelihood. This strategy appeals to the common approach of defining a quasi-
likelihood from estimating equations by considering the dual quadratic minimization problem
(see, for example, Green 1984; McCullagh 1991).
4.3 The quasi-likelihood information criterion
We now address selection of the blip model. Based on the preceding derived quasi-likelihoods,
we propose an information criterion whose general form builds on standard likelihood the-
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ory, where the Kullback-Leibler divergence between a proposed model and the true, data-
generating model is minimized.
Under standard regularity conditions on the quasi-likelihood function Q(.), inference pro-
ceeds in the usual way for misspecified models. Let f(y) denote the true, data-generating
distribution, and let γ(y;ψ(m)) denote a proposed blip model which, combined with treat-
ment and treatment-free models, fully specifies the G-estimating quasi-likelihood, Q(y;ψ(m)),
and the corresponding density fm(y) ≡ f(y;ψ(m)). The proposed blip model is taken from a
class of candidate models,M(m) = {γ(y;ψ(m))|ψ(m) ∈ Ψ(m)} with fitted models γ(y; ψ̂(m)).
The divergence between f(y) and fm(y) estimated using the observed data and ψ̂(m) is given
(up to an additive constant) by δ(ψ̂(m)) = E[−2Q(Y ;ψ)]|ψ(m)=ψ̂(m), computed with ψ̂(m)
fixed, and the expected divergence is given by ∆(m) = E[δ(ψ̂(m))]; in the latter expression,
the expectation is over the distribution of the estimator ψ̂(m). All expectations are taken
with respect to the true distribution f(y) by considering independent copies of the data.
Let ψ(m,∗) = argminψ(m)∈Ψ(m)Q(y;ψ(m)). If the true blip function is parametric and
contained inM(m), then ψ(m,∗) is the “true” parameter; if the set of candidate models does
not contain the true blip, then ψ(m,∗) is the value such that Q(y;ψ(m,∗)) provides the best
approximation to f(y) in the sense of minimizing the expected Kullback-Leibler divergence.
Under standard regularity conditions on Q(.), we have that ψ̂(m) is consistent for ψ(m,∗), and
√
n(ψ̂(m) −ψ(m,∗)) d−→ Normal(0,V(ψ(m,∗)))
where V is a positive definite matrix given by V(ψ) = I(ψ)−1J (ψ)I(ψ)−1 where, for ψ′ ∈
N , an open neighborhood of ψ(m,∗)
I(ψ′) = E
[
−∂
2Q1(ψ)
∂ψ∂ψ⊤
]∣∣∣∣
ψ=ψ′
J (ψ′) = E
[{
∂Q1(ψ)
∂ψ
}{
∂Q1(ψ)
∂ψ
}⊤]∣∣∣∣∣
ψ=ψ′
.
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and
∂Q1(ψ)
∂ψ
= D1A1hψ1(Y
∗
1 − µ∗1(ψ))
is the G-estimating function inspired by (5) for the first data point.
Theorem: Suppose thatQ(ψ) is twice continuously differentiable with bounded expectation
of its second derivative in an open neighborhood N of ψ(m,∗). Then, under the stable unit
treatment value and no unmeasured confounding assumptions (detailed in Subsection 2.1),
the expected divergence ∆(m) can be approximated as
∆(m) = E[−2Q(ψ(m,∗))] + 2tr
{J (ψ(m,∗))I(ψ(m,∗))−1}+ o(1)
which is consistently estimated by
QICG(m) = ∆̂(m) = −2Q(ψ̂(m)) + 2tr{J(ψ̂(m))I(ψ̂(m))−1}
where I(.) and J(.) are the observed (empirical) versions of I and J . Thus, the model
selection procedure that chooses a model by minimizing QICG(m) across M(m) identifies
the model that minimizes ∆(m) with probability 1 as n −→∞.
Proof : see Supplementary Material.
This result gives rise to our quasi-likelihood information criterion, which in terms of the
estimator of the asymptotic variance V, V̂ (ψ̂) = nI(ψ̂)−1J(ψ̂)I(ψ̂)−1, may be written
QICG = −2Q(ψ̂) + 2tr{I(ψ̂)V̂ (ψ̂))}. (7)
In their derivation of a related criterion, Taguri et al. (2014) use a direct sandwich estimator
for V. However, while this allows a slight simplification of expression (7), we note that this
approach fails to accommodate all sources of uncertainty. The estimation of the parameters
α of the treatment model at each interval should be acknowledged, and as we move through
14
stages recursively estimation of all previous parameters should be similarly accommodated;
this is achieved through the application of Taylor expansions to the estimating function
U(ψ) (Robins 2004; Moodie 2009), although in our experience such corrections make little
difference to the resulting variance estimates.
Our derivation of the QIC also differs from that of Taguri et al. (2014) in two substantial
ways. First, the estimation of β̂ is corrected for automatically by its substitution in the
estimation of ψ̂, that is, using implicit forms β(ψ) in the linear model or the IRLS recursion
for the log-linear model. That is, we do not estimate the treatment-free model parameters
β in a separate calculation using only the untreated individuals. Secondly, our derivation
of the quasi-likelihood matches that of Taguri et al. (2014) in the linear case, however their
approach cannot be extended to the log-linear case.
The form of (7) is typical in information criterion-style approaches (Takeuchi 1976), and
writing K = tr{I(ψ̂)V̂ (ψ̂))} we may present it as QICG = −2Q(ψ̂) + 2K to more clearly
evoke this similarity. This criterion may be applied at each stage of the G-estimation process
with the blip model returning the lowest criterion value being recommended, as in a more
typical analysis. Note, however, that it is necessary to assume that at all but the first stage
of treatment an at-worst overspecified blip model is contained within the set of candidate
models as otherwise poor parameter estimation can have a cumulative effect. Similarly,
we must assume that at least one of the treatment or treatment-free models is correctly
specified, so that the resulting blip parameter estimators are consistent. These assumptions
are necessary for any recursive procedure.
The above theory extends to the case of continuous treatments. The primary complication
is that the blip function is extended to include a quadratic treatment term, so that the
optimal treatment at any given stage may lie inside the range of possible values it may take
(Rich et al. 2014). After this modification, we can proceed to define an equivalent quasi-
likelihood (and quasi-likelihood information criterion) at each stage of treatment. Full details
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are included in the Supplementary Material.
5. ANALYSIS
In this section, we first use simulations to demonstrate the IRLS approach to G-estimation for
a count outcome and to demonstrate the performance of the QICG in a continuous outcome
scenario. We then proceed to apply both IRLS and the quasi-likelihood information criterion
to an empirical analysis, performing analyses which treat the (discrete) outcome as either
continuous or as a count.
5.1 Simulation study: IRLS for a log-linear SNMM
First, we present an illustration of the IRLS algorithm for G-estimation in the case of a
log-linear outcome model. Simulating a two-stage example, we generate data as follows:
• stage 1 patient information: X1 ∼ N(0, 1);
• stage 1 treatment: a1 ∈ {0, 1}, P (A1 = 1|h1) = expit(x1);
• stage 2 patient information: X2 ∼ N(a1, 1);
• stage 2 treatment: a2 ∈ {0, 1}, P (A2 = 1|h2) = expit(x2);
• stage j blip: γj(aj , xj) = aj(ψj0 + ψj1xj1) such that a
opt
j = 1{ψj0+ψj1xj1>0};
• outcome: P (Y = k) = λke−k/k!,
with λ = exp
[
β0 + log(|x1|)−
∑2
j=1[γj(a
opt
j , xj)− γj(aj , xj)]
]
.
For all simulations we set (ψj0, ψj1) = (0.5,−0.5), j = 1, 2. As described in section 3.1,
one concern in extending G-estimation to discrete outcomes is that of zero values in the
response, and the effect they can have on the stage-specific pseudo-outcomes. Replacing the
0 with 0.001 when computing the pseudo-outcome, we investigate the performance of the
algorithm in three sets of simulations with varying values for β0, chosen to yield outcomes
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with approximately 5%, 10% and 20% zeros. Our analyses correctly specified the treatment
model, but mis-specified the treatment-free model, supposing it was linear in x1 in contrast
to the true log(|x1|) term. Initial simulation runs had unacceptably high rates of failure to
converge. To address this we adjusted the IRLS algorithm detailed above slightly, introducing
step-halving whereby the initial parameter estimates at each iteration were the mean of the
previous two stages, and ignoring the termination condition dependent on |µ(t) − µ(t−1)|,
instead terminating when only |η(t)−η(t−1)| dropped below a given tolerance. This reduced
convergence failure rates to 3% or lower.
We generated 1000 simulated datasets per setup, setting the tolerance ǫη to 0.001 and
limiting the number of iterations at each stage to 1000. Exploratory analyses of smaller
simulation runs with lower tolerances and larger iteration limits did not yield substantially
different results for parameter estimates or failure rates. Results are summarized (Table 1),
where stage 1 estimates for the covariate-by-treatment interaction are slightly (though not
statistically significantly) biased in small samples. Bias does not appear to be related to the
probability of zero-outcomes, although standard errors appear to increase with it.
Table 1: Mean blip parameter estimates (standard errors) from 1000 simulation runs for
log-linear outcome model via iteratively-reweighted least squares. True blip parameters
(ψj0, ψj1) of (0.5,−0.5).
n P (Y = 0) ψ̂10 (SE) ψ̂11 (SE) ψ̂20 (SE) ψ̂21 (SE)
50 5% 0.485 (0.337) -0.349 (0.260) 0.487 (0.320) -0.437 (0.372)
10% 0.511 (0.370) -0.345 (0.295) 0.500 (0.348) -0.449 (0.407)
20% 0.523 (0.418) -0.339 (0.343) 0.496 (0.388) -0.445 (0.461)
100 5% 0.503 (0.209) -0.427 (0.155) 0.497 (0.217) -0.475 (0.235)
10% 0.501 (0.226) -0.428 (0.165) 0.496 (0.232) -0.470 (0.247)
20% 0.520 (0.248) -0.419 (0.191) 0.504 (0.266) -0.483 (0.287)
200 5% 0.501 (0.144) -0.471 (0.101) 0.504 (0.153) -0.486 (0.166)
10% 0.501 (0.154) -0.471 (0.109) 0.502 (0.163) -0.486 (0.171)
20% 0.510 (0.174) -0.470 (0.124) 0.501 (0.186) -0.484 (0.198)
500 5% 0.498 (0.089) -0.485 (0.062) 0.502 (0.095) -0.496 (0.102)
10% 0.497 (0.095) -0.485 (0.066) 0.505 (0.100) -0.495 (0.110)
20% 0.502 (0.107) -0.485 (0.077) 0.500 (0.114) -0.495 (0.120)
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5.2 Simulation study: QICG
Next, we demonstrate the use of QICG in the DTR framework with a variety of simulated
two-stage examples from the continuous outcome setting (we present results for the discrete-
outcome setting in the Supplementary Material). We generate data as follows:
• stage 1 patient information: X1k ∼ N(0, 1) for k = 1, 2, 3;
• stage 1 treatment: a1 ∈ {0, 1}, P (A1 = 1|h1) = expit(x11 + x12 + x13);
• stage 2 patient information: X2k ∼ N(a1, 1) for k = 1, 2, 3;
• stage 2 treatment: a2 ∈ {0, 1}, P (A2 = 1|h2) = expit(x21 + x22 + x23);
• stage j blip: γj(aj ,hj) = aj(1 + ψj1xj1 + ψj2xj2 + ψj3xj3)
such that aoptj = 1{1+ψj1xj1+ψj2xj2+ψj3xj3>0};
• outcome: Y = −∑2j=1[γj(aoptj ,hj)− γj(aj,hj)] + ǫ, with ǫ ∼ log-normal(0, 1)− e0.5;
where expit(x) = [1 + exp(−x)]−1 is the expit or inverse-logit function. We have used skewed
errors in our generation of the outcome (centralized to have mean zero) to better illustrate
the potential benefits of the QICG approach. Results using normal errors are included in
the Supplementary Material for reference. In our first analyses, we consider datasets of size
n = 50, 100 and 200, and set the blip parameters to (ψj1, ψj2, ψj3) = (1, 0, 0), (1, 1, 0) or
(1, 1, 1) giving a range of models including one, two, or all three variables at each stage.
We conducted a G-estimation analysis of 1000 simulated datasets considering eight dif-
ferent blip models corresponding to each of the possible combinations of the predictors
at each stage (that is, using none, one, two or all three). The treatment models were
always correctly specified (and modeled using logistic regression), while the treatment-
free models E[Gj(ψj)|hβj;βj] were linear with covariates (1, x11, x12, x13) at stage 1 and
(1, x11, x12, x13, a1x11, a1x12, a1x13, x21, x22, x23) at stage 2 (i.e. using all available covariates).
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Using QICG, we performed forward and backward selection within the set of candidate
models as in a standard AIC-type stepwise analysis. For comparison we also conducted
forward and backward selection based on Wald test p-values at a 0.05 significance level. For
these initial simulations, stage 1 results are based on analysis carried out following fitting
of the correct model at stage 2. Results (Table 2) indicate QICG outperforms the Wald-
type approaches except for the smallest true models (although even then it largely remains
competitive). Furthermore, while QICG shows a slight tendency to overfit, the Wald-type
approaches show considerably more bias towards underfitting. In addition, we note a slightly
greater consistency between the forward and backward QICG results than between the Wald
test results, suggesting QICG may be more robust to choice of selection direction.
Table 2: Model selection for a variety of sample sizes (n). Numbers indicate proportion of
1000 simulation runs where the correct model was selected by the corresponding method.
(F) and (B) denote forwards and backwards selection, respectively. Bold indicates the most
successful approach for each setup.
n Model QICG (F) QICG (B) Wald (F) Wald (B)
50 x11 0.285 0.276 0.303 0.297
x11, x12 0.232 0.238 0.137 0.160
x11, x12, x13 0.218 0.259 0.060 0.108
x21 0.225 0.216 0.263 0.248
x21, x22 0.203 0.213 0.119 0.145
x21, x22, x23 0.181 0.214 0.068 0.09
100 x11 0.437 0.423 0.479 0.471
x11, x12 0.373 0.380 0.284 0.318
x11, x12, x13 0.372 0.419 0.181 0.254
x21 0.372 0.366 0.422 0.418
x21, x22 0.353 0.365 0.263 0.285
x21, x22, x23 0.357 0.381 0.150 0.205
200 x11 0.533 0.530 0.606 0.601
x11, x12 0.569 0.573 0.484 0.519
x11, x12, x13 0.587 0.628 0.379 0.451
x21 0.479 0.477 0.581 0.577
x21, x22 0.505 0.507 0.439 0.453
x21, x22, x23 0.538 0.557 0.334 0.371
In these multi-stage simulations, all methods perform better in selection of the first
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stage blip model rather than the second due to the first stage being a simpler model fitting
problem: at stage 2 both first and second stage covariates affect analysis. We note however
that the recursive nature of the G-estimation approach means that the analysis of the first
stage happens subsequent to analysis of the second stage, using estimates obtained from that
stage which we might expect to affect stage 1 model assessment. It seems that any impact
this aspect of the estimation process might have is small compared to the inherent simplicity
that earlier stages involve fewer covariates.
Moreover, in the results for stage 1 model assessment we have ignored the problem of stage
2 model selection, and instead fixed the stage 2 model as the correct one. While in reality
this is an implicit assumption we must make, it seems prudent to investigate what impact
this may have on model selection. We conduct analyses identical to those above (limited
to n = 100) but with two other approaches to model selection. In addition to the ‘best-
case’ scenario of selecting the correct stage 2 model, we also investigate the consequences
of choosing the model recommended by the model selection procedures themselves, and a
‘worst-case’ scenario where intercept-only models are used (Table 3). These non-optimal
approaches do result in a drop in performance, but this is not particularly dramatic (and
not statistically significant) even in the worst-case scenario. We note, however, that in more
complex setups it is likely mis-specification of the stage 2 models could have more dramatic
consequences for stage 1 model selection.
We also investigated the impact of other aspects of our data generation setup. Weaker
effect sizes (simulated by setting the blip parameters to 0.1 and 0.5 instead of 1 as above)
predictably resulted in lower success rates across all the methods under consideration. How-
ever, the quasi-likelihood approach was much more resilient to these effects. Introducing a
correlation structure among the non-treatment covariates also resulted in worse model selec-
tion, but again the quasi-likelihood approach appeared to be slightly more robust to these
changes. Results of these additional scenarios are included in the Supplementary Material.
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Table 3: Stage 1 model selection (n = 100) when the stage 2 model is correctly specified
(‘Correct’), selected by the corresponding approach (‘Recommended’), or an intercept-only
model (‘Intercept’). Numbers indicate proportion of 1000 simulation runs where the correct
model was selected by the corresponding method. (F) and (B) denote forwards and back-
wards selection, respectively. Bold indicates the most successful approach for each setup.
Selection Model QICG (F) QICG (B) Wald (F) Wald (B)
Correct x11 0.437 0.423 0.479 0.471
x11, x12 0.373 0.380 0.284 0.318
x11, x12, x13 0.372 0.419 0.181 0.254
Recommended x11 0.420 0.409 0.485 0.471
x11, x12 0.369 0.375 0.283 0.316
x11, x12, x13 0.372 0.417 0.175 0.250
Intercept x11 0.431 0.417 0.479 0.469
x11, x12 0.373 0.380 0.283 0.311
x11, x12, x13 0.373 0.411 0.167 0.245
These results were aggregated across the various model setups at each stage to afford
greater simplicity in the presentation of our results. For example, the results corresponding
to the stage 1 blip model which only included x11 were taken from simulations across the
three different stage 2 blip models. Non-aggregated results (see Supplementary Material)
show little evidence of stage 2 model complexity affecting stage 1 selection or vice-versa.
5.3 Investigating the trace term
We have framed our QICG in terms of the quasi-likelihood and a ‘penalty term’ defined in
terms of the trace K = tr{I(ψ̂)V̂ (ψ̂)}. In the likelihood-based setting it is known that
this trace term may, if the model under consideration is a good approximation of the truth,
be approximated by the dimension of that model (Burnham and Anderson 2002; Shibata
1989). Here, the quasi-likelihood is grounded in estimating equation theory and so, if the
error terms in the outcome generating model were normally distributed, we might expect a
similar result. This is complicated by our estimation of two other models besides the blip,
as well as the recursive multi-stage nature of the G-estimation framework.
We summarize estimates of the term K from our first set of simulations above with
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n = 100 in a figure in the supplement, with the modification that we generate the error term
ǫ in the outcome from a standard normal distribution rather than log-normal. In general, the
estimates appear to be similar to the dimension of the corresponding model, particularly at
the second stage, when the correct model was used. If two models of the same dimension are
compared then on average an incorrect model will result in a slightly larger trace term than
that from a correct model. Stage 1 estimates of the trace in general seem to be slightly lower.
These results assume correct specification of the treatment model, ensuring consistency of our
estimators as per the double-robustness property of G-estimation. We have found (results
omitted) that when both treatment and treatment-free models are mis-specified the resulting
trace terms can be much larger. In addition, if the distribution of the error term ǫ is skewed,
as in the previously reported results, then the trace term is again much larger. This suggests
the possibility of comparing the trace term with candidate model dimension to investigate
the validity of the treatment and treatment-free models, following use of residual plots (or
similar techniques) to assess the normality of the residuals.
We note finally that the use of bootstrap procedures to estimate the trace (or penalty)
term tr{I(ψ̂)V̂ (ψ̂)} have been recommended in preference to the use of termwise plug-
in versions of matrices I(.) and J(.) (see Burnham and Anderson (2002)). We have not
investigated this possibility in our analysis as the plug-in procedure appears to work well in
our examples, and due to the additional computational burden. Bootstrap procedures are
valid for inference in the regular G-estimation setting (see for example Shortreed and Moodie
(2012)), and are straightforward, although computationally expensive, to implement.
5.4 Sequenced Treatment Alternatives to Relieve Depression study
We now illustrate application of our proposed IRLS and QICG approaches to real data from
the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. STAR*D was
a multi-stage randomized control trial designed to compare different treatment regimes for
patients with major depressive disorder (Fava et al. 2003; Rush et al. 2004). The study was
22
split into 4 levels (one of which was itself split into two sub-levels), with patients receiving
a different treatment or combination of treatments within each level.
At study entry (level 1) patients were prescribed citalopram and followed up at regu-
larly scheduled clinic visits. Those whose depression did not enter remission – defined as a
Quick Inventory of Depressive Symptomatology (QIDS) score less than or equal to 5 – could
proceed to a second level of treatment where seven treatment options were available. The
second level of treatment was characterized by ‘switching’ from citalopram to one of four
new treatments, or ‘augmenting’ the current treatment by receiving citalopram alongside
one of three other treatment options. Patients who received cognitive therapy at level 2
(either alone or combined with citalopram) were eligible to enter the sublevel 2A where they
received one of the treatments available at level 2. All patients without remission could then
proceed to level 3 (and, if their depression persisted, a further level 4) where again their pre-
vious treatment was either switched to or augmented with a number of options. Full details
of the study design and treatment options, are described elsewhere (Rush et al. 2004).
An important aspect of the study is that patients were asked for their treatment prefer-
ence and would then be randomized to one of the treatment options consistent with their
preference. This is typically characterized as patients choosing to ‘switch’ from their current
treatment to, or ‘augment’ it with, a different one, although the reality was slightly more
complex. In particular, when moving from level 1 to level 2, patients were asked about their
preference to switch or augment their current treatment with cognitive therapy separately to
their preference to switch or augmenting with a pharmacological (i.e., drug-based) treatment.
We conduct an analysis following Chakraborty et al. (2013) who investigated the di-
chotomy between treatments that were, or included, a selective serotonin reuptake inhibitor
(SSRI) and those that did not. We restrict attention to two stages of the study and consider
level 2 (including level 2A) and level 3 as our first and second stages of treatment, respec-
tively. Treatment at each stage was coded as 1 if an SSRI was received, either alone or in
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combination, with level 2A treatments (both of which were non-SSRI) combined with level 2
treatments for this purpose. Treatment was coded as 0 if no SSRI was received throughout
a stage. Of 1,027 total patients, only 273 entered level 3. Our outcome is defined as negative
QIDS score at end of treatment (i.e., at the end of stage 2 if a patient entered level 3, and
at the end of stage 1 otherwise). By taking the negative, larger values are preferred, and
we therefore seek a DTR that maximizes this outcome. We pursue an analysis analogous
to those undertaken by previous authors, viewing QIDS score as a continuous outcome, and
then use our new IRLS-based approach and the associated QICG to apply a log-linear model.
We consider the following tailoring variables: QIDS score measured at the start of the
corresponding level (denoted qj for stage j), the change in QIDS score divided by time across
the previous level (QIDS slope, denoted sj), and patient preference prior to receiving treat-
ment (pj). Patient preference is binary and coded as 1 if the patient rejected all treatments
consistent with switching to a different pharmacological treatment, and 0 otherwise. The
assumed treatment model at each stage was fit by logistic regression of observed treatment
on preference only, while the treatment-free models are specified as:
• stage 1: E[G1(ψ1)|hβ1;β1] = β10 + q1β11 + s1β12 + p1β13; and
• stage 2: E[G2(ψ2)|hβ2;β2] = β20 + q2β21 + s2β22 + p2β23 + a1β24.
We consider the ‘full’ blip models
• stage 1: γ1(hψ1, a1;ψ1) = a1(ψ10 + q1ψ11 + s1ψ12 + p1ψ13); and
• stage 2: γ2(hψ2, a2;ψ2) = a2(ψ20 + q2ψ21 + s2ψ22),
and investigate all sub-models (every covariate combination from the full models, including
intercept-only models). There are eight candidate models at stage 1, and four at stage 2.
Rather than proceed directly to a stepwise procedure, we instead fit all possible models as
dimensionality was low. G-estimation was therefore first performed four times: once for each
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of the candidate stage 2 blip models, with an intercept-only blip model specified at stage
1 (this choice not affecting stage 2 analysis). The lowest value of QICG was found when
the intercept-only model was used, suggesting it is the best choice of stage 2 blip model
(based on either a forward or backward selection procedure). This result was reinforced by
application of both Wald-type approaches of the previous section.
We then repeated the analysis for each of the eight candidate stage 1 blip models using
the recommended stage 2 blip model, and found that the model containing stage 1 preference
only returned the lowest QICG (and would be recommended by either a forward or backward
procedure). The Wald-type approaches also both recommended the preference-only model.
Our log-linear analyses were based on a similar setup with treatment-free and blip models
exponentiated, adding 27 to all outcome measures to ensure they were positive. Applying
G-estimation via IRLS and computing QICG for every blip model we found the same models
recommended at each stage. We observe that in all analyses the same model was recom-
mended at stage 1 regardless of which stage 2 model was chosen.
Overall, these results are broadly consistent with the analysis of Chakraborty et al.
who, despite using the somewhat different approach of Q-learning, found that no stage 2
blip covariates were statistically significant, while stage 1 preference alone was significant
in the stage 1 blip model. It is encouraging that QICG for both modeling setups indicated
the preference term should be included. We also find that at both stages both estimation
processes predict the same optimal treatment for every patient.
Finally, we can compare observed outcomes among patients based on how consistent their
observed treatments were with the optimal ones as recommended by our models. Among
patients who entered stage 2, mean improvement in QIDS score among those who received
optimal treatment at both stages, one stage, or no stages was, respectively, 4.67 (sd = 3.92,
n = 15), 3.80 (sd = 6.08, n = 75), and 2.56 (sd = 5.19, n = 183). Among patients who did
not enter stage 2, mean improvement was 6.13 (sd = 4.72, n = 145) for those who received
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optimal treatment, and 5.49 (sd = 4.84, n = 609) for those who did not.
6. DISCUSSION
Personalized medicine and the development of dynamic treatment regimes is an important
frontier in biostatistical research. This has been reflected in a rapidly expanding literature
focusing on DTR estimation techniques, but more practical concerns have received compar-
atively little attention. In this paper we have presented two extensions to the G-estimation
framework. First, we have demonstrated how G-estimation may be applied for log-linear
models via iteratively-reweighted least squares; this provides a relatively straightforward
route to G-estimation use in a greater variety of contexts. Further, we have presented an
approach to model selection for SNMMs within the DTR framework. By demonstrating
how G-estimation in its typical application (for continuous treatments) may be reduced to
a relatively simple form, we have derived a quasi-likelihood for each stage of a multi-stage,
recursive analysis process. We have then extended the work of Pan (2001) and Taguri et al.
(2014) to derive a general quasi-likelihood information criterion for DTR estimation using G-
estimation. Furthermore, while we have focused on the binary treatment setting, the theory
extends to the case of a continuous treatment, dramatically increasing its applicability.
Our simulations involving log-linear SNMMs indicate how G-estimation may be imple-
mented for discrete outcomes with relative ease, especially if extant IRLS routines in standard
software packages can be used for this purpose. We note that there may be further room to
improve on the approximation used to handle the zero-outcomes, which at present are set
to a very small number only when the non-optimal treatment was received. This concern
extends to the binary outcome setting, where estimation is even more problematic: the ‘blip’
cannot be separated from the treatment-free component of the mean using a logit transfor-
mation, and the use of a log-linear model only provides reasonable (unbiased) estimators in
a small range of settings. The question of how to construct pseudo-outcomes that better
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address this issue is an avenue for further research. Note, finally, that if the (counterfactual)
outcomes are binary, then modeling the expected counterfactual on the usual logistic scale
is problematic for G-estimation, as it is not possible to separate the blip component from
the treatment-free expected counterfactual component, as would be the case on the linear
or log-linear scale. This issue warrants further attention.
Through simulation studies we have shown that our quasi-likelihood information criterion
performs as well as or better than simpler Wald-type approaches for continuous outcomes,
particularly when sample or effect sizes are small, or there is correlation between candidate
covariates. In addition, we found greater agreement between the forward and backward
stepwise approaches when using QICG than the Wald-type approach, a potentially attrac-
tive feature in practice. We note, however, that QICG does seem to overfit, and as such
slight modifications may lead to more balanced results. We have experimented with ad hoc
corrections inspired by the Bayesian Information Criterion and the corrected AIC, which
have yielded promising results. Moreover while one may often argue that for the purposes
of an explanatory analysis, compared with underfitting, overfitting is the less serious error,
this is perhaps more justified in a multi-stage setting where mis-specification by underfitting
can have a more severe knock-on effect in our analysis. When the outcome was generated
using normal errors, rather than the skewed log-normal errors discussed here, the Wald-type
approaches become more competitive, but still badly underfit (full results are included in
the Supplementary Material). As in any simulation-based analysis we appreciate that the
results presented here cannot possibly be comprehensive, and so would encourage further
experimentation (and analysis) to assess the properties of these various criteria. Of partic-
ular interest is a more extensive investigation of the QICG for discrete outcomes, with our
preliminary analyses providing encouraging results.
The trace term, K, warrants additional research. In our simulations we observed that
when errors were normally distributed, and the blip model correctly specified, K was ap-
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proximately equal to the dimension of the model (as is the case in the likelihood-based
setting). This was not generally the case, however, especially when both the treatment and
treatment-free models were badly mis-specified or errors were non-normal. From a practical
perspective, the quasi-likelihood criteria presented may tend to underfit when models are
mis-specified (as the corresponding penalty term is large), but if the researcher has doubts
about the legitimacy of parameter estimators (due to mis-specification of both the treatment
and treatment-free models), then model selection is a secondary concern. In our analysis
of the STAR*D data we found that for the various candidate models, the trace term was
somewhat larger than the dimension of the associated blip function while residual plots from
the proposed models were consistent with normal errors. This could indicate an inadequacy
in the treatment or treatment-free models which might merit further investigation.
Our QIC formulation has focused exclusively on selection of the blip, or contrast, compo-
nent of the outcome mean model. However, the approach can easily be adapted to select the
entire mean model (the contrast and treatment-free models simultaneously), allowing the use
of our information criterion for G-estimation of static treatment sequences or G-estimation
for mediation, as well as in binary outcome settings.
7. SUPPLEMENTARY MATERIAL
Appendix: Appendix containing additional theory, and simulation results.
R code: R code for the simulation studies of section 5 and the Appendix.
Appendix: Supplementary Material for Manuscript titled “General-
ized G-estimation and Model Selection”
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8. QUASI-LIKELIHOOD FOR CONTINUOUS TREATMENTS
In the binary treatment setting we showed that our estimating equations U(ψ) may be
reduced to
U(ψ) = (Dhψ)
⊤
[
(In − ĥβ)(y˜ −Ahψψ)
]
.
We now extend to the case of a continuous treatment and include a quadratic term in our
blip such that
γ(hψ, a;ψ1,ψ2) = ahψ1ψ1 + a
2hψ2ψ2
where we have compartmentalized our blip parameters ψ = (ψ1,ψ2) and history design ma-
trix hψ = (hψ1 ,hψ2) depending on whether they are associated with the linear or quadratic
term of a in our blip. Writing D1 and D2 for the diagonal matrices with (i, i)
th entry
ai −E[Ai|Hi] and a2i −E[A2i |Hi], respectively, our estimating equations become (Rich et al.
2014)
U(ψ) =
 D1hψ1
D2hψ2

⊤ [
(In − ĥβ)(y˜ −Ahψ1ψ1 −A2hψ2ψ2)
]
, which yields a quasi-likelihood of the form
Q(ψ) = ψ⊤
 D1hψ1
D2hψ2

⊤ [
(In − ĥβ)y˜
]
− 1
2
ψ⊤
 D1hψ1
D2hψ2

⊤(
Ahψ1,A
2hψ2
)⊤
ψ
= ψ⊤mc − 1
2
ψ⊤Mcψ
where mc and Mc may be thought of as the continuous treatment analogs to m and M
derived in the main paper for the binary case.
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9. PROOF OF DISCREPANCY THEOREM
Recall the theorem from section 2.4 of the associated paper:
Theorem: Suppose that Q(ψ) is twice continuously differentiable with bounded expecta-
tion of its second derivative in a neighbourhood N of ψ(m,∗). Then, under the stable unit
treatment value and no unmeasured confounding assumptions (detailed in section 2.1), the
expected divergence ∆(m) can be approximated
∆(m) = E[−2Q(ψ(m,∗))] + 2tr
{J (ψ(m,∗))I(ψ(m,∗))−1}+ o(1)
which is consistently estimated by
QICG(m) = ∆̂(m) = −2Q(ψ̂(m)) + 2tr{J(ψ̂(m))I(ψ̂(m))−1}
where I(.) and J(.) are the observed (empirical) versions of I and J . Thus, the model
selection procedure that chooses a model by minimizing QICG(m) across M(m) identifies
the model that minimizes ∆(m) with probability 1 as n −→∞.
Proof : Following Takeuchi (1976) – see also Burnham and Anderson (2002) – our quasi-
likelihood information criterion (QIC) is based on an estimate of ∆(m), a function of the
Kullback-Leibler discrepancy between the data generating model and model m. Consider a
decomposition of ∆(m) = E[δ(ψ̂(m))], where
δ(ψ̂(m)) = E[−2Q(Y ;ψ)]|ψ(m)=ψ̂(m),
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given by
∆(m) =
{
E[δ(ψ̂(m))]−E[−2Q(ψ(m,∗)]
}
+
{
E[−2Q(ψ(m,∗))]− E[−2Q(ψ̂(m))]
}
+ E[−2Q(ψ̂(m))].
We consider first an expansion of Q(.) around the “true” blip parameter for model m, ψ(m,∗):
we have that
Q(ψ̂(m)) = Q(ψ(m,∗)) + Q˙(ψ(m,∗))(ψ̂(m) −ψ(m,∗))
+
1
2
(ψ̂(m) −ψ(m,∗))⊤Q¨(ψ(m,∗))(ψ̂(m) −ψ(m,∗)) + op(1)
so taking expectations with respect to the data generating model with ψ̂(m) fixed, we have
E[−2Q(ψ̂(m))] = E[−2Q(ψ(m,∗))]− (ψ̂(m) −ψ(m,∗))⊤I(ψ(m,∗))(ψ̂(m) −ψ(m,∗)) + o(1)
where, recall,
I(ψ′) = E
[
−∂
2Q1(ψ)
∂ψ∂ψ⊤
]∣∣∣∣
ψ=ψ′
and hence
E[−2Q(ψ(m,∗))]− E[−2Q(ψ̂(m))] = (ψ̂(m) −ψ(m,∗))⊤I(ψ(m,∗))(ψ̂(m) −ψ(m,∗)) + o(1).
Using the conventional theory of misspecified models, we have that
√
n(ψ̂(m) −ψ(m,∗)) =
{
I(ψ(m,∗))
}−1 × 1√
n
n∑
i=1
Q˙(Yi;ψ(m,∗)) + op(1)
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where, by construction of the quasi-likelihood function, we have
Q˙(y;ψ) ≡ U(y;ψ).
Hence
√
n(ψ̂(m) −ψ(m,∗)) d−→ Normal(0, I(ψ(m,∗))−1J (ψ(m,∗))I(ψ(m,∗))−1)
as n −→∞, where
J (ψ′) = E
[{
∂Q(ψ)
∂ψ
}{
∂Q(ψ)
∂ψ
}⊤]∣∣∣∣∣
ψ=ψ′
and
I(ψ′) = −1
n
∂2Q(ψ)
∂ψ∂ψ⊤
∣∣∣∣
ψ=ψ′
J(ψ′) =
1
n
[
∂Q(ψ)
∂ψ
{
∂Q(ψ)
∂ψ
}⊤]
ψ=ψ′
.
By standard convergence results
(ψ̂(m)−ψ(m,∗))⊤I(ψ(m,∗))(ψ̂(m)−ψ(m,∗)) = (ψ̂(m)−ψ(m,∗))⊤I(ψ(m,∗))(ψ̂(m)−ψ(m,∗)) + op(1)
and by a standard result for quadratic forms
E[(ψ̂(m) −ψ(m,∗))⊤I(ψ(m,∗))(ψ̂(m) −ψ(m,∗))] = tr
{J (ψ(m,∗))[I(ψ(m,∗))]−1}+ o(1).
Under standard regularity conditions on Q(.), we have that ψ̂(m)
p−→ ψ(m,∗) as n −→ ∞,
and hence for large n E[−2Q(ψ̂(m))] = E[−2Q(ψ(m,∗))] + o(1), so
∆(m) = E[−2Q(ψ(m,∗))] + E[(ψ̂(m) −ψ(m,∗))⊤I(ψ(m,∗))(ψ̂(m) −ψ(m,∗))] + o(1)
≡ E[−2Q(ψ(m,∗))] + 2tr
{J (ψ(m,∗))[I(ψ(m,∗))]−1}+ o(1).
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This completes the proof.
The asymptotic variance of estimator ψ̂(m) may itself be estimated by
V̂ (ψ̂(m)) = nI(ψ̂(m))
−1J(ψ̂(m))I(ψ̂(m))
−1.
10. INVESTIGATING THE TRACE TERM
We examine in simulation whether the trace term is a good approximation to the true
dimension of the underlying model when that model is fitted, as described in section 5.3 of
the main paper. Figure 1 displays estimates of stage 1 (top) and stage 2 (bottom) trace term
K from 1,000 simulations with n = 100 for different candidate models (y-axis). The panels
correspond to true blip models containing an intercept term along with stage j covariates
xj1 (left), xj1, xj2 (middle), xj1, xj2, xj3 (right), and gray boxes correspond to simulations
where the true blip model was fit. In expectation, the trace term matches the dimension of
the data generating model even in this relatively small sample setting.
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Figure 1: Trace Component Term. Estimates of stage 1 (top) and stage 2 (bottom) trace
term K from 1,000 simulations with n = 100 for different candidate models (y-axis). Plots
correspond to true blip models containing an intercept term along with stage j covariates
xj1 (left), xj1, xj2 (middle), xj1, xj2, xj3 (right). Gray boxes correspond to simulations where
the true blip model was fit.
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11. SIMULATION RESULTS
11.1 Discrete Outcome
Next, we demonstrate the use of QICG in the DTR framework for a discrete outcome case.
We generate data as follows:
• stage 1 patient information: X11 ∼ N(1, 1), X12 ∼ N(−1, 1), X13 ∼ N(1, 1);
• stage 1 treatment: a1 ∈ {0, 1}, P (A1 = 1|h1) = expit(x11);
• stage 2 patient information: X21 ∼ N(a1, 1), X22 ∼ N(−1, 1), X23 ∼ N(1, 1);
• stage 2 treatment: a2 ∈ {0, 1}, P (A2 = 1|h2) = expit(x21);
• stage j blip: γj(aj ,hj) = aj(0.5 + ψj1xj1 + ψj2xj2 + ψj3xj3)
such that aoptj = 1 if 0.5 + ψj1xj1 + ψj2xj2 + ψj3xj3 > 0 and 0 otherwise;
• outcome: P (Y = k) = λke−k/k!,
with λ = exp
[
β0 −
∑2
j=1[γj(a
opt
j ,hj)− γj(aj ,hj)]
]
,
where we vary β0 so that for the various ψjk we consider, P (Y = 0) = 0.1. We set the
blip parameters to (ψj1, ψj2, ψj3) = (0.5, 0, 0), (0.5, 0.5, 0) or (0.5, 0.5, 0.5) giving a range of
models including one, two, or all three variables at each stage.
Given the computational requirements for the IRLS algorithm, our simulations are some-
what more limited. We restrict ourselves to sample sizes of n = 200, and only consider the
four blip models containing no covariates, xj1 only, xj1 and xj2 only, or all three covari-
ates, and choose whichever model resulted in the lowest QICG. As with our simulations in
the main paper (Table 1), we correctly specify our treatment model, and mis-specify the
treatment-free model, supposing it is linear in x11 at stage 1 and linear in x21 at stage 2.
Results are summarized in Table 4, where the stage 1 results are based on analyses where
the stage 2 blip models were correctly specified. The IRLS algorithm was implemented
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with an iteration limit of 1,000 and a tolerance limit (between successive log-mean function
estimates) of 0.001.
The presented results summarize over the simulation runs where all four IRLS algorithms
converged. This corresponds to all 1,000 simulated datasets for the simplest models (with
only one covariate in the true blip model at each stage), 996 (stage 2) and 994 (stage 1)
datasets when two covariates were included, and 904 (stage 2) and 863 (stage 1) datasets
where all three were included. If we instead presume model selection is based on the lowest
QIC only for those candidate blip models where IRLS converged (as might occur in a real-life
analysis), results were near-identical with the slight exception of model selection for the most
complex blip model at both stages. In this case, the correct model selection rate drops from
0.921 to 0.833 for stage 2, and from 0.919 to 0.877 for stage 1, with the largest candidate
model most likely to result in failure.
Table 4: Model selection (n = 200) for discrete outcome case. Entries are selection rates for
the model indicated by the column heading. Bold indicates correct model selection rate.
True Intercept xj1 xj1, xj2 xj1, xj2, xj3
x11 0.017 0.663 0.169 0.151
x11, x12 0.001 0.004 0.799 0.196
x11, x12, x13 0.001 0.002 0.078 0.919
x21 0.005 0.617 0.189 0.189
x21, x22 0.001 0.006 0.836 0.157
x21, x22, x23 0.000 0.002 0.076 0.921
11.2 Continuous Outcome
Additional simulation results referred to in the main paper. Table 5 contains results for
varying effect sizes, Table 6 contains results for varying correlation strength between covari-
ates, and Table 7 contains non-aggregated results. Tables 8-12 contain analogous results to
Tables 1-2 in the main paper and Tables 5-7 in this appendix, but with standard normal
errors in the generation of the outcome Y , rather than log-normal errors. In all tables bold
indicates the most successful method for each scenario.
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Table 5: Model selection (n = 100) with true blip parameters of 1, 0.5, or 0.1, under the setup
described in section 3.2. (F) and (B) denote forwards and backwards selection, respectively.
Bold indicates most successful approach for each setup.
ψjp Model QICG (F) QICG (B) Wald (F) Wald (B)
1 x11 0.437 0.423 0.479 0.471
x11, x12 0.373 0.380 0.284 0.318
x11, x12, x13 0.372 0.419 0.181 0.254
x21 0.372 0.366 0.422 0.418
x21, x22 0.353 0.365 0.263 0.285
x21, x22, x23 0.357 0.381 0.150 0.205
0.5 x11 0.267 0.259 0.215 0.208
x11, x12 0.160 0.169 0.071 0.086
x11, x12, x13 0.128 0.165 0.033 0.063
x21 0.232 0.229 0.219 0.214
x21, x22 0.162 0.177 0.077 0.089
x21, x22, x23 0.132 0.156 0.028 0.049
0.1 x11 0.122 0.120 0.073 0.072
x11, x12 0.043 0.048 0.005 0.012
x11, x12, x13 0.021 0.037 0.000 0.002
x21 0.138 0.138 0.076 0.073
x21, x22 0.053 0.063 0.016 0.02
x21, x22, x23 0.030 0.045 0.003 0.003
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Table 6: Model selection (n = 100) with non-treatment covariates drawn from multivariate
normal distributions with correlations of 0 (‘none’), 0.25 (‘medium’) and 0.5 (‘strong’), under
the setup described in section 3.2. (F) and (B) denote forwards and backwards selection,
respectively. Bold indicates most successful approach for each setup.
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Table 7: Non-aggregated selection (n = 100), under the setup described in section 3.2.
(F) and (B) denote forwards and backwards selection, respectively. Bold indicates most
successful approach for each setup.
Stage 1 Stage 2 QICG (F) QICG (B) Wald (F) Wald (B)
Stage 1 Selection
x11 x21 0.437 0.422 0.492 0.481
x21, x22 0.443 0.429 0.476 0.467
x21, x22, x23 0.432 0.417 0.469 0.465
x11, x12 x21 0.383 0.388 0.287 0.328
x21, x22 0.367 0.373 0.288 0.321
x21, x22, x23 0.370 0.378 0.276 0.306
x11, x12, x13 x21 0.392 0.434 0.189 0.274
x21, x22 0.366 0.418 0.183 0.247
x21, x22, x23 0.359 0.406 0.171 0.241
Stage 2 Selection
x11 x21 0.373 0.370 0.426 0.424
x11, x12 0.375 0.366 0.418 0.411
x11, x12, x13 0.367 0.362 0.421 0.419
x11 x21, x22 0.364 0.375 0.275 0.299
x11, x12 0.351 0.364 0.255 0.278
x11, x12, x13 0.345 0.356 0.258 0.278
x11 x21, x22, x23 0.358 0.386 0.162 0.215
x11, x12 0.361 0.386 0.142 0.202
x11, x12, x13 0.351 0.371 0.147 0.198
96, 998–1004.
Moodie, E. E. M., Dean, N., and Sun, Y. R. (2014), “Q-learning: Flexible learning about
useful utilities,” Statistics in Biosciences, 6, 223–243.
Pan, W. (2001), “Akaike’s information criterion in generalized estimating equations,” Bio-
metrics, 57, 120–125.
Rich, B., Moodie, E. E. M., Stephens, D. A., and Platt, R. W. (2010), “Model checking with
residuals for G-estimation of optimal dynamic treatment regimes,” International Journal
of Biostatistics, 6(2), Article 12.
Rich, B., Moodie, E. E. M., and Stephens, D. A. (2014), “Adaptive individualized dosing
39
Table 8: Model selection for a variety of sample sizes (n), under the setup described in
section 3.2 but with normal (rather than log-normal) errors ǫ ∼ N(0, 1). (F) and (B) denote
forwards and backwards selection, respectively. Bold indicates most successful approach for
each setup.
n Model QICG (F) QICG (B) Wald (F) Wald (B)
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Table 9: Stage 1 model selection (n = 100) when the stage 2 model is correctly specified
(‘Correct’), selected by the corresponding approach (‘Recommended’), or an intercept-only
model (‘Intercept’), under the setup described in section 3.2 but with normal (rather than
log-normal) errors ǫ ∼ N(0, 1). (F) and (B) denote forwards and backwards selection,
respectively. Bold indicates most successful approach for each setup.
Selection Model QICG (F) QICG (B) Wald (F) Wald (B)
Correct x11 0.556 0.543 0.767 0.763
x11, x12 0.643 0.646 0.644 0.705
x11, x12, x13 0.796 0.842 0.513 0.652
Recommended x11 0.555 0.541 0.750 0.748
x11, x12 0.636 0.641 0.627 0.692
x11, x12, x13 0.784 0.831 0.492 0.629
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x11, x12 0.628 0.633 0.576 0.640
x11, x12, x13 0.730 0.776 0.419 0.557
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Table 10: Model selection (n = 100) with true blip parameters of 1, 0.5, or 0.1, under the
setup described in section 3.2 but with normal (rather than log-normal) errors ǫ ∼ N(0, 1).
(F) and (B) denote forwards and backwards selection, respectively. Bold indicates most
successful approach for each setup.
ψjp Model QICG (F) QICG (B) Wald (F) Wald (B)
1 x11 0.556 0.543 0.767 0.763
x11, x12 0.643 0.646 0.644 0.705
x11, x12, x13 0.796 0.842 0.513 0.652
x21 0.489 0.481 0.637 0.639
x21, x22 0.574 0.582 0.539 0.571
x21, x22, x23 0.676 0.706 0.410 0.485
0.5 x11 0.387 0.379 0.378 0.377
x11, x12 0.308 0.318 0.164 0.201
x11, x12, x13 0.265 0.322 0.071 0.127
x21 0.297 0.293 0.310 0.305
x21, x22 0.273 0.280 0.142 0.158
x21, x22, x23 0.217 0.247 0.060 0.088
0.1 x11 0.130 0.127 0.075 0.076
x11, x12 0.039 0.044 0.006 0.012
x11, x12, x13 0.014 0.028 0.002 0.006
x21 0.132 0.131 0.104 0.105
x21, x22 0.058 0.064 0.022 0.024
x21, x22, x23 0.027 0.032 0.000 0.003
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Table 11: Model selection (n = 100) with non-treatment covariates drawn from multivariate
normal distributions with correlations of 0 (‘none’), 0.25 (‘medium’) and 0.5 (‘strong’), under
the setup described in section 3.2 but with normal (rather than log-normal) errors ǫ ∼
N(0, 1). (F) and (B) denote forwards and backwards selection, respectively. Bold indicates
most successful approach for each setup.
Correlation Model QICG (F) QICG (B) Wald (F) Wald (B)
None x11 0.556 0.543 0.767 0.763
x11, x12 0.643 0.646 0.644 0.705
x11, x12, x13 0.796 0.842 0.513 0.652
x21 0.489 0.481 0.637 0.639
x21, x22 0.574 0.582 0.539 0.571
x21, x22, x23 0.676 0.706 0.410 0.485
Medium x11 0.510 0.502 0.666 0.661
x11, x12 0.588 0.594 0.550 0.570
x11, x12, x13 0.714 0.732 0.451 0.493
x21 0.468 0.460 0.585 0.584
x21, x22 0.509 0.517 0.443 0.459
x21, x22, x23 0.578 0.597 0.324 0.363
Strong x11 0.470 0.466 0.586 0.587
x11, x12 0.525 0.526 0.445 0.449
x11, x12, x13 0.563 0.574 0.282 0.293
x21 0.407 0.402 0.494 0.488
x21, x22 0.410 0.413 0.316 0.322
x21, x22, x23 0.402 0.410 0.190 0.178
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Table 12: Non-aggregated selection (n = 100), under the setup described in section 3.2 but
with normal (rather than log-normal) errors ǫ ∼ N(0, 1). (F) and (B) denote forwards and
backwards selection, respectively. Bold indicates most successful approach for each setup.
Stage 1 Stage 2 QICG (F) QICG (B) Wald (F) Wald (B)
Stage 1 Selection
x11 x21 0.551 0.535 0.775 0.773
x21, x22 0.561 0.546 0.766 0.764
x21, x22, x23 0.557 0.547 0.762 0.756
x11, x12 x21 0.645 0.647 0.650 0.712
x21, x22 0.637 0.641 0.634 0.699
x21, x22, x23 0.646 0.649 0.651 0.706
x11, x12, x13 x21 0.799 0.839 0.525 0.663
x21, x22 0.794 0.842 0.507 0.644
x21, x22, x23 0.794 0.846 0.511 0.653
Stage 2 Selection
x11 x21 0.498 0.490 0.642 0.643
x11, x12 0.491 0.481 0.646 0.643
x11, x12, x13 0.477 0.473 0.623 0.631
x11 x21, x22 0.591 0.600 0.558 0.589
x11, x12 0.582 0.589 0.541 0.576
x11, x12, x13 0.548 0.556 0.519 0.548
x11 x21, x22, x23 0.702 0.729 0.443 0.512
x11, x12 0.667 0.700 0.408 0.484
x11, x12, x13 0.658 0.688 0.380 0.460
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